Adenovirus serotype 35 vector-mediated transduction following direct administration into organs of nonhuman primates

Gene Therapy

Volumn 16, Issue 2, 2009, Pages 297-302

  Sakurai, F ^a   Nakamura, S I ^a,b   Akitomo, K ^a   Shibata, H ^a   Terao, K ^a   Kawabata, K ^a   Hayakawa, T ^c,d   Mizuguchi, H ^a,e  

^a NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^b The Corporation for Production and Research of Laboratory Primates   (Japan)

^c PHARMACEUTICALS AND MEDICAL DEVICES AGENCY   (Japan)

^d KINKI UNIVERSITY   (Japan)

^e OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; MEMBRANE COFACTOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONJUNCTIVA EPITHELIUM; CONTROLLED STUDY; ENDOTHELIUM CELL; FIBROBLAST; GENE EXPRESSION; LEG MUSCLE; LIVER CELL; MACROPHAGE; MICROGLIA; MONKEY; NONHUMAN; PRIORITY JOURNAL; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS STRAIN; VITREOUS BODY; ADENOVIRIDAE; ADMINISTRATION AND DOSAGE; ANIMAL; BIOSYNTHESIS; CLASSIFICATION; GENE EXPRESSION REGULATION; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; INJECTION; MACACA FASCICULARIS; METABOLISM; TISSUE DISTRIBUTION; TOPICAL DRUG ADMINISTRATION;

ADENOVIRIDAE; ADMINISTRATION, TOPICAL; ANIMALS; ANTIGENS, CD46; BETA-GALACTOSIDASE; GENE EXPRESSION REGULATION; GENETIC VECTORS; INJECTIONS; MACACA FASCICULARIS; TISSUE DISTRIBUTION; TRANSDUCTION, GENETIC; TRANSGENES;

ADENOVIRIDAE; MACACA FASCICULARIS; PRIMATES;

EID: 60449106707     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2008.154     Document Type: Article

References (30)

1. Havenga MJ, Lemckert AA, Ophorst OJ, van Meijer M, Germeraad WT, Grimbergen J et al. Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease. J Virol 2002; 76 4612-4620.
2. De Jong JC, Wermenbol AG, Verweij-Uijterwaal MW, Slaterus KW, Wertheim-Van Dillen P, Van Doornum GJ et al. Adenoviruses from human immunodeficiency virus-infected individuals, including two strains that represent new candidate serotypes Ad50 and Ad51 of species B1 and D, respectively. J Clin Microbiol 1999; 37: 3940-3945.
3. Lemckert AA, Sumida SM, Holterman L, Vogels R, Truitt DM, Lynch DM et al. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. J Virol 2005; 79: 9694-9701.
4. Nanda A, Lynch DM, Goudsmit J, Lemckert AA, Ewald BA, Sumida SM et al Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys. J Virol 2005; 79: 14161-14168.
5. Mizuguchi H, Hayakawa T. Enhanced antitumor effect and reduced vector dissemination with fiber-modified adenovirus vectors expressing herpes simplex virus thymidine kinase. Cancer Gene Ther 2002; 9: 236-242.
6. Okada Y, Okada N, Mizuguchi H, Hayakawa T, Mayumi T, Mizuno N. An investigation of adverse effects caused by the injection of high-dose TNFalpha-expressing adenovirus vector into established murine melanoma. Gene Therapy 2003; 10: 700-705.
7. Suzuki T, Sakurai F, Nakamura S, Kouyama E, Kawabata K, Kondoh M et al. miR-122a-regulated expression of a suicide gene prevents hepatotoxicity without disturbing the antitumor effects in suicide gene therapy. Mol Ther 2008, (in press).
8. Sakurai F, Mizuguchi H, Hayakawa T. Efficient gene transfer into human CD34+ cells by an adenovirus type 35 vector. Gene Therapy 2003; 10: 1041-1048.
9. Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, de Bethune MP et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: Efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 2003; 77: 8263-8271.
10. Gao W, Robbins PD, Gambotto A. Human adenovirus type 35: Nucleotide sequence and vector development. Gene Therapy 2003; 10: 1941-1949.
11. Seshidhar Reddy P, Ganesh S, Limbach MP, Brann T, Pinkstaff A, Kaloss M et al. Development of adenovirus serotype 35 as a gene transfer vector. Virology 2003; 311: 384-393.
12. Sakurai F, Mizuguchi H, Yamaguchi T, Hayakawa T. Characterization of in vitro and in vivo gene transfer properties of adenovirus serotype 35 vector. Mol Ther 2003; 8: 813-821.
13. Sakurai F, Kawabata K, Koizumi N, Inoue N, Okabe M, Yamaguchi T et al Adenovirus serotype 35 vector-mediated transduction into human CD46-transgenic mice. Gene Therapy 2006; 13: 1118-1126.
14. Verhaagh S, de Jong E, Goudsmit J, Lecollinet S, Gillissen G, de Vries M et al. Human CD46-transgenic mice in studies involving replication-incompetent adenoviral type 35 vectors. J Gen Virol 2006; 87: 255-265.
15. Sakurai F, Nakamura S, Akitomo K, Shibata H, Terao K, Kawabata K et al. Transduction properties of adenovirus serotype 35 vectors after intravenous administration into nonhuman primates. Mol Ther 2008; 16: 726-733.
16. Sakai M, Nishikawa M, Thanaketpaisarn O, Yamashita F, Hashida M. Hepatocyte-targeted gene transfer by combination of vascularly delivered plasmid DNA and in vivo electroporation. Gene Therapy 2005; 12: 607-616.
17. Crettaz J, Berraondo P, Mauleon I, Ochoa L, Shankar V, Barajas M et al. Intrahepatic injection of adenovirus reduces inflammation and increases gene transfer and therapeutic effect in mice. Hepatology 2006; 44: 623-632.
18. Bora NS, Gobleman CL, Atkinson JP, Pepose JS, Kaplan HJ. Differential expression of the complement regulatory proteins in the human eye. Invest Ophthalmol Vis Sci 1993; 34: 3579-3584.
19. Thirion C, Lochmuller H, Ruzsics Z, Boelhauve M, Konig C, Thedieck C et al. Adenovirus vectors based on human adenovirus type 19a have high potential for human muscle-directed gene therapy. Hum Gene Ther 2006; 17: 193-205.
20. Danko I, Williams P, Herweijer H, Zhang G, Latendresse JS, Bock I et al. High expression of naked plasmid DNA in muscles of young rodents. Hum Mol Genet 1997; 6: 1435-1443.
21. Wang AY, Peng PD, Ehrhardt A, Storm TA, Kay MA. Comparison of adenoviral and adeno-associated viral vectors for pancreatic gene delivery in vivo. Hum Gene Ther 2004; 15: 405-413.
22. Hierholzer JC. Adenoviruses in the immunocompromised host. Clin Microbiol Rev 1992; 5: 262-274.
23. Sakurai F, Nakamura S, Akitomo K, Shibata H, Terao K, Hayakawa T et al. Transduction properties of adenovirus serotype 35 vectors after intravenous administration in non-human primates. Mol Ther 2008; 16: 726-733.
24. Shirakawa T, Terao S, Hinata N, Tanaka K, Takenaka A, Hara I et al Long-term outcome of phase I/II clinical trial of Ad-OC-TK/VAL gene therapy for hormone-refractory metastatic prostate cancer. Hum Gene Ther 2007; 18: 1225-1232.
25. Shimada H, Matsubara H, Shiratori T, Shimizu T, Miyazaki S, Okazumi S et al. Phase I/II adenoviral p53 gene therapy for chemoradiation resistant advanced esophageal squamous cell carcinoma. Cancer Sci 2006; 97: 554-561.
26. Tong AW, Nemunaitis J, Su D, Zhang Y, Cunningham C, Senzer N et al Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. Mol Ther 2005; 11 160-172.
27. Catanzaro AT, Koup RA, Roederer M, Bailer RT, Enama ME, Moodie Z et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 2006; 194: 1638-1649.
28. Rosenberg SA, Zhai Y, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 1998; 90: 1894-1900.
29. Stewart DJ, Hilton JD, Arnold JM, Gregoire J, Rivard A, Archer SL et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: A phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Therapy 2006; 13: 1503-1511.
30. Rosengart TK, Lee LY, Patel SR, Kligfield PD, Okin PM, Hackett NR et al. Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Ann Surg 1999; 230: 466-470; discussion 470-472.